FrancophonIA/ELRC3.0 huggingface dataset:
English: In a 3 month clinical study, approximately 29% of patients treated with LUMIGAN 0.3 mg/mL singledose experienced adverse reactions.
Danish: I et 3-måneders klinisk studie oplevede ca. 29 % af de patienter, som blev behandlet med LUMIGAN 0,3 mg/ml enkeltdosisformulering, bivirkninger.
English: If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.
Danish: Hvis flere topikale øjenlægemidler anvendes, bør administration af hver enkelt ske med mindst 5 minutters mellemrum.
English: If you use LUMIGAN 0.3 mg/mL single-dose with another eye medicine, wait at least 5 minutes between using LUMIGAN 0.3 mg/mL single-dose and the other eye medicine.
Danish: Hvis De bruger anden øjenmedicin, skal der gå mindst fem minutter imellem, at De bruger LUMIGAN 0,3 mg/ml enkeltdosis og den anden øjenmedicin.
English: In a 6-month clinical study with LUMIGAN 0.3 mg/mL (multi-dose formulation), versus latanoprost, a statistically superior reduction in morning mean IOP (ranging from -7.6 to -8.2 mmHg for bimatoprost versus -6.0 to -7.2 mmHg for latanoprost) was observed at all visits throughout the study.
Danish: I et 6-måneders klinisk studie med LUMIGAN 0,3 mg/ml (flerdosisformulering) til sammenligning med latanoprost observeredes et statistisk større fald i middelværdien for IOT om morgenen (fra -7,6 til -8,2 mmHg for bimatoprost versus -6,0 til -7,2 mmHg for latanoprost) ved samtlige besøg gennem hele studiet.
English: BOTTLE
Danish: FLASKE
English: In clinical studies, LUMIGAN was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
Danish: I kliniske undersøgelser blev LUMIGAN anvendt samtidig med et antal forskellige oftalmiske betablokerende øjenmidler uden tegn på interaktioner.
English: In rat peri/postnatal studies, maternal toxicity caused reduced gestation time, foetal death, and decreased pup body weights at  0.3 mg/kg/day (at least 41-times the intended human exposure).
Danish: I peri- og postnatale studier med rotter bevirkede toksicitet hos moderdyret nedsat drægtighedsperiode, fosterdød og nedsat legemsvægt hos ungerne ved doser på 0,3 mg/kg/døgn (mindst 41 gange den tilsigtede humane eksponering).
English: In a 6-month clinical study with LUMIGAN 0.3 mg/ml, versus latanoprost, a statistically superior reduction in morning mean IOP (ranging from -7.6 to -8.2 mmHg for bimatoprost versus -6.0 to -7.2 mmHg for latanoprost) was observed at all visits throughout the study.
Danish: I et 6-måneders klinisk forsøg med LUMIGAN 0,3 mg/ml til sammenligning med latanoprost observeredes et statistisk større fald i middelværdien for IOT om morgenen (fra -7,6 til -8,2 mmHg for bimatoprost versus -6,0 til -7,2 mmHg for latanoprost) ved samtlige besøg gennem hele forsøget.
English: In rat peri/postnatal studies, maternal toxicity caused reduced gestation time, foetal death, and decreased pup body weights at 0.3 mg/kg/day (at least 41-times the intended human exposure).
Danish: I peri- og postnatale forsøg med rotter bevirkede toksicitet hos moderdyret nedsat drægtighedsperiode, fosterdød og nedsat legemsvægt hos ungerne ved doser på 0,3 mg/kg/døgn (mindst 41 gange den tilsigtede humane eksponering).
English: • Irritation, when drop is put in the eye
Danish: • Irritation nå øjet dryppes
English: In a 12-month Phase III clinical study approximately 38 % of patients treated with LUMIGAN 0.1 mg/ml eye drops, solution experienced adverse reactions.
Danish: I et 12 måneders fase III klinisk forsøg oplevede ca. 38 % af de patienter, der blev behandlet med LUMIGAN 0,1 mg/ml øjendråber bivirkninger.
English: At 12 months, the incidence of iris hyperpigmentation with bimatoprost 0.1 mg/ml eye drops, solution was 0.5%.
Danish: Efter 12 måneder var incidensen af irishyperpigmentering med bimatoprost 0,1 mg/ml øjendråber 0,5 %.
English: What LUMIGAN 0.3 mg/mL single-dose contains - The active substance is bimatoprost.
Danish: LUMIGAN 0,3 mg/ml enkeltdosis indeholder: - Aktivt stof: Bimatoprost.
English: Skin and subcutaneous tissue disorders common skin hyperpigmentation, hypertrichosis uncommon dry skin, eyelid margin crusting, pruritus not known skin discoloration (periocular)
Danish: Hud og subkutane væv almindelig hyperpigmentering af hud, hypertrikose ikke almindelig tør hud, skorpedannelse på kanterne af øjenlågene, pruritus ikke kendt misfarvning af huden (periokulær)
English: Skin and subcutaneous tissue disorders common pigmentation of periocular skin uncommon hirsutism not known skin discoloration (periocular)
Danish: Hud og subkutane væv almindelig pigmentering af periokulære hud ikke almindelig hirsutisme ikke kendt misfarvning af huden (periokulær)
English: • Worsening vision
Danish: • Dårligere syn
English: At 3 months, the incidence of iris hyperpigmentation with bimatoprost 0.3 mg/mL single dose was 0.3%.
Danish: Efter 3 måneder var incidensen af irishyperpigmentering med bimatoprost 0,3 mg/ml (enkeltdosisformulering) 0,3 %.
English: Limited experience is available with the use of LUMIGAN in patients with open-angle glaucoma with pseudoexfoliative and pigmentary glaucoma, and chronic angle-closure glaucoma with patent iridotomy.
Danish: Der er begrænsede erfaringer med anvendelse af LUMIGAN hos patienter med åbenvinklet glaukom med pseudoexfoliativ og pigment glaukom og kronisk vinkel-lukket glaukom med åben iridotomi.
English: The following pack sizes are available:
Danish: Lumigan fås i følgende pakninger:
English: OUTER CARTON CONTAINING 30 SINGLE-DOSE CONTAINERS
Danish: YDRE ÆSKE MED 30 ENKELTDOSISBEHOLDERE
English: Other medicines and LUMIGAN 0.3 mg/mL single-dose Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Danish: Brug af anden medicin sammen med LUMIGAN +0,3 mg/ml enkeltdosis: Fortæl altid lægen eller på apoteket, hvis De bruger anden medicin eller har gjort det for nylig.
English: In clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/mL (multi-dose formulation).
Danish: I kliniske studier er over 1.800 patienter blevet behandlet med LUMIGAN 0,3 mg/ml (flerdosisformulering).
English: Most were ocular, mild and none was serious.
Danish: De fleste var okulære, lette og ingen var alvorlige.
English: Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.
Danish: Bivirkninger indberettet for phosphatholdige øjendråber Hornhindeforkalkning i forbindelse med brug af øjendråber, som indeholder phosphat er i meget sjældne tilfælde rapporteret hos patienter med signifikant beskadigede hornhinder.
English: Reporting side effects
Danish: Indberetning af bivirkninger
English: • conjunctival hyperaemia (mostly trace to mild and thought to be of a non-inflammatory nature) in up to 44% in the first year with the incidence of new reports decreasing to 13% at 2 years and 12% at 3 years
Danish: • konjunktival hyperæmi (for det meste en antydning eller en mild form, som anses for ikkeinflammatorisk) hos op til 44% i løbet af det første år, hvorefter incidensen af nye indberetninger faldt til 13% efter 2 år og 12% efter 3 år
English: Limited experience is available in patients with open-angle glaucoma with pseudoexfoliative and pigmentary glaucoma, and chronic angle-closure glaucoma with patent iridotomy.
Danish: Der er begrænsede erfaringer hos patienter med åbenvinklet glaukom med pseudoexfoliativ og pigment glaukom og kronisk vinkel-lukket glaukom med åben iridotomi.
English: LUMIGAN 0.1 mg/ml eye drops contains BAK in a concentration of 200 ppm.
Danish: LUMIGAN 0,1 mg/ml øjendråber indeholder benzalkoniumchlorid i en koncentration på 200 ppm (0,2 mg/ml).
English: If you use more LUMIGAN 0.3 mg/mL single-dose than you should If you use more of this medicine than you should, it is unlikely to cause you any serious harm.
Danish: Hvis De har brugt for meget LUMIGAN 0,3 mg/ml enkeltdosis Hvis De har brugt for meget af dette lægemiddel, er det usandsynligt, at det skulle forårsage nogen skade.
English: In clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/ml.
Danish: I kliniske forsøg er over 1800 patienter blevet behandlet med LUMIGAN 0,3 mg/ml.
English: • Nausea
Danish: • Kvalme
English: There have been rare spontaneous reports of reactivation of previous corneal infiltrates or ocular infections with bimatoprost 0.3 mg/ml eye drops, solution.
Danish: Der har været sjældne spontane rapporter om reaktivering af tidligere cornealinfiltrat eller øjeninfektioner med bimatoprost 0,3 mg/ml øjendråber.
English: • Swelling of the see-through layer that covers the eye
Danish: • Hævelse af det gennemsigtige lag, der dækker øjet
English: At 12 months, the incidence of iris pigmentation with bimatoprost 0.3mg/ml was 1.5% (see section 4.8) and did not increase following 3 years treatment.
Danish: Efter 12 måneder var incidensen af irispigmentering med bimatoprost 0,3 mg/ml 1,5 % (se pkt 4.8), og den steg ikke efter 3 års behandling.
English: Check with your doctor or pharmacist if you are not sure.
Danish: Spørg lægen eller apoteket, hvis der er noget, De er i tvivl om.
English: Discard four weeks after first opening.
Danish: Kasseres 4 uger efter åbning.
English: White opaque low density polyethylene bottles with polystyrene screw cap. Each bottle has a fill volume of 3 ml.
Danish: Hvide, uigennemsigtige flasker af lavdensitetspolyethylen med polystyrenskruelåg.
English: In clinical studies, bimatoprost 0.3 mg/ml, eye drops, solution was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
Danish: I kliniske undersøgelser blev bimatoprost 0,3 mg/ml øjendråber anvendt samtidig med et antal forskellige oftalmiske beta-blokerende øjenmidler uden tegn på interaktioner.
English: Do not use LUMIGAN 0.1 mg/ml: - if you are allergic to bimatoprost or any of the other ingredients of this medicine (listed in section
Danish: Brug ikke LUMIGAN 0,1 mg/ml - hvis De er allergisk over for bimatoprost eller et af de øvrige indholdsstoffer i LUMIGAN 0,1
English: In addition to the adverse reactions seen with LUMIGAN 0.3 mg/mL single-dose, Table 3 lists additional adverse reactions that were seen with LUMIGAN 0.3 mg/mL (multi-dose formulation).
Danish: Ud over de bivirkninger, der ses med LUMIGAN 0,3 mg/ml enkeltdosisformulering, viser tabel 3 yderligere bivirkninger, som er set med LUMIGAN 0,3 mg/ml (flerdosisformulering).
English: After once daily ocular administration of one drop of LUMIGAN 0.3 mg/mL to both eyes for two weeks, blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit of detection (0.025 ng/ml) within 1.5 hours after dosing.
Danish: Efter administration af 1 dråbe LUMIGAN 0,3 mg/ml dagligt i begge øjne i 2 uger toppede blodkoncentrationer inden for 10 minutter efter dosering og faldt til under den laveste påviselige grænse (0,025 ng/ml) inden for 1,5 time efter dosering.
English: LUMIGAN is an antiglaucoma preparation.
Danish: LUMIGAN er et lægemiddel til behandling af glaukom (grøn stær).
English: After once daily ocular administration of one drop of 0.3 mg/ml bimatoprost to both eyes for two weeks, blood concentrations peaked within 10 minutes after dosing and declined to below the lower limit of detection (0.025 ng/ml) within 1.5 hours after dosing.
Danish: Efter 1 daglig okulær administration af 1 dråbe 0,3 mg/ml bimatoprost i begge øjne i 2 uger toppede blodkoncentrationer inden for 10 minutter efter dosering og faldt til under den laveste påviselige grænse (0,025 ng/ml) inden for 1,5 time efter dosering.
English: • Swelling of the surface of the eye
Danish: • Hævelse af øjets overflade
English: • Slight redness (up to 29 % of people)
Danish: • Let rødme (hos op til 29 %)
English: After twice daily dosing of LUMIGAN 0.3 mg/mL, the mean AUC0-24hr value of 0.0634 ng•hr/ml bimatoprost in the elderly (subjects 65 years or older) were significantly higher than 0.0218 ng•hr/ml in young healthy adults.
Danish: Efter administration af LUMIGAN 0,3 mg/ml 2 gange dagligt var den gennemsnitlige AUC0-24t-værdi på 0,0634 ng•t/ml bimatoprost hos ældre (forsøgspersoner over 65 år) signifikant højere end værdien på 0,0218 ng•t/ml hos unge raske voksne.
English: Benzalkonium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate, sodium chloride, hydrochloric acid or sodium hydroxide (to adjust pH) and purified water
Danish: Benzalkoniumchlorid, dinatriumphosphatheptahydrat, citronsyremonohydrat, natriumchlorid, saltsyre eller natriumhydroxyd (til indstilling af pH) og renset vand
English: - You have or have had low blood pressure or low heart rate - You have had a viral infection or inflammation of the eye
Danish: - Hvis De tidligere har fået en grå stær-operation - Hvis De har eller har haft lavt blodtryk eller langsomt hjerteslag - Hvis De har haft en virusinfektion eller betændelse i øjet
English: After twice daily dosing with bimatoprost 0.3 mg/ml eye drops, solution, the mean AUC0-24hr value of 0.0634 ng•hr/ml bimatoprost in the elderly (subjects 65 years or older) were significantly higher than 0.0218 ng•hr/ml in young healthy adults.
Danish: Efter 1 dosis 2 gange om dagen med bimatoprost 0,3 mg/ml øjendråber var den gennemsnitlige AUC024t-værdi på 0,0634 ng•t/ml bimatoprost hos ældre (forsøgspersoner over 65 år) signifikant højere end værdien på 0,0218 ng•t/ml hos unge raske voksne.
English: Bimatoprost was not mutagenic or carcinogenic in a series of in vitro and in vivo studies.
Danish: I en række in vitro- og in vivo-studier udviste bimatoprost hverken mutagen eller karcinogen aktivitet.
English: Most were ocular, mild to moderate, and none was serious:
Danish: De fleste var okulære, lette til moderate, og ingen var alvorlige:
English: Do not use LUMIGAN 0.3 mg/ml: - if you are allergic to bimatoprost or any of the other ingredients of this medicine (listed in section
Danish: Brug ikke LUMIGAN 0,3 mg/ml - hvis De er allergisk over for bimatoprost eller et af de øvrige indholdsstoffer i LUMIGAN 0,3
English: Less than 9 % of patients discontinued due to any adverse event in the first year with the incidence of additional patient discontinuations being 3 % at both 2 and 3 years.
Danish: Færre end 9 % af patienterne seponerede behandlingen på grund af en bivirkning i løbet af det første år, og incidensen af yderligere patienter, der ophørte med behandlingen, var 3 % i løbet af både 2. og 3. år.
English: Nervous system disorders uncommon headache not known dizziness
Danish: Nervesystemet ikke almindelig hovedpine ikke kendt svimmelhed
English: There have been rare spontaneous reports of reactivation of previous corneal infiltrates or ocular infections with bimatoprost 0.3 mg/mL eye drops, solution (multi-dose formulation).
Danish: Der har været sjældne spontane rapporter om reaktivering af tidligere cornealinfiltrat eller øjeninfektioner med bimatoprost 0,3 mg/ml øjendråber, opløsning (flerdosisformulering).
English: • Inflammation within the eye
Danish: • Vævsirritation i øjet
English: LUMIGAN 0.3 mg/ml is contraindicated in patients who have had a suspected previous adverse reaction to benzalkonium chloride that has led to discontinuation.
Danish: LUMIGAN 0,3 mg/ml er kontraindiceret hos patienter, der tidligere har har seponeret en behandling på grund af en formodet uønsket reaktion på benzalkoniumchlorid.
English: The recommended dose is one drop of LUMIGAN in the evening, once daily in each eye that needs treatment.
Danish: Den anbefalede dosis er 1 dråbe LUMIGAN en gang daglig om aftenen i det øje/de øjne, som skal behandles.
English: LUMIGAN 0.1 mg/ml is contraindicated in patients who have had a suspected previous adverse reaction to benzalkonium chloride that has led to discontinuation.
Danish: LUMIGAN 0,1 mg/ml er kontraindiceret hos patienter, der tidligere har seponeret en behandling på grund af en formodet uønsket reaktion på benzalkoniumchlorid.
English: Most were ocular, mild to moderate, and none were serious.
Danish: De fleste var okulære, lette til moderate, og ingen var alvorlige.
English: LUMIGAN 0.1 mg/ml contains the preservative benzalkonium chloride (200 ppm), which may be absorbed by soft contact lenses.
Danish: LUMIGAN 0,1 mg/ml indeholder konserveringsmidlet benzalkoniumchlorid, som kan absorberes af bløde kontaktlinser.
English: What LUMIGAN 0.3 mg/ml looks like and contents of the pack LUMIGAN is a colourless clear eye drop solution in a pack containing either 1 plastic bottle or 3 plastic bottles each with a screw cap. Each bottle is approximately half full and contains 3 millilitres of solution.
Danish: LUMIGANs 0,3 mg/ml udseende og pakningsstørrelse LUMIGAN er en farveløs klar øjendråbeopløsning i en pakning, der indeholder enten 1 plastflaske eller 3 plastflasker med skruelåg.
English: The recommended dose is one drop once daily, in the evening, once daily in each eye that needs treatment.
Danish: Den sædvanlige dosis er 1 dråbe en gang dagligt om aftenen i det øje/de øjne, som skal behandles.
English: LUMIGAN 0.3 mg/mL single-dose should only be applied to the eye
Danish: LUMIGAN 0,3 mg/ml enkeltdosis må kun anvendes som øjendråber.
English: • Darker Iris colour
Danish: • Mørkere farve på iris
English: LUMIGAN may get into breast milk so you should not breast-feed while you are taking LUMIGAN.
Danish: LUMIGAN udskilles måske i mælken og må derfor ikke anvendes af ammende kvinder.
English: During 12 months' monotherapy treatment with LUMIGAN 0.3 mg/mL (multi-dose formulation) in adults, versus timolol, mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mmHg.
Danish: Under 12 måneders monoterapi med LUMIGAN 0,3 mg/ml (flerdosisformulering) hos voksne, hvor der sammenlignedes med timolol, varierede middelændringen i intraokulært tryk (IOT) fra baseline om morgenen (08.00) med -7,9 til -8,8 mmHg.
English: 10 single-dose containers
Danish: 10 enkeltdosisbeholdere.
English: Compared to treatment with beta-blocker alone, adjunctive therapy with beta-blocker and LUMIGAN 0.3 mg/mL (multi-dose formulation) lowered mean morning (08:00) intraocular pressure by -6.5 to -8.1 mmHg.
Danish: Sammenlignet med monoterapi med beta-blokker sænkede behandling med beta-blokker suppleret med LUMIGAN 0,3 mg/ml (flerdosisformulering) middelværdien for intraokulært tryk om morgenen (08.00) med -6,5 til -8,1 mmHg.
English: LUMIGAN 0.3 mg/mL single-dose may get into breast milk so you should not breast-feed while you are taking this medicine.
Danish: LUMIGAN 0,3 mg/ml enkeltdosis udskilles måske i mælken, og bør derfor ikke anvendes af ammende kvinder.
English: The following adverse reactions were reported during clinical trials with LUMIGAN 0.1 mg/ml eye drops, solution or in the post-marketing period.
Danish: Følgende bivirkninger blev indberettet i kliniske forsøg med LUMIGAN 0,1 mg/ml øjendråber eller i perioden efter markedsføring.
English: EXP Once the pouch is opened, the single dose containers should be used within 30 days.
Danish: EXP Enkeltdosisbeholderne skal anvendes senest 30 dage efter åbning af posen.
English: - The other ingredients are benzalkonium chloride (preservative), sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate and purified water.
Danish: - Øvrige indholdsstoffer: Benzalkoniumchlorid (konserveringsmiddel), natriumchlorid, dinatriumphosphatheptahydrat, citronsyremonohydrat og renset vand.
English: - If you have further questions, ask your doctor or pharmacist.
Danish: Er De i tvivl, så spørg lægen eller på apoteket.
English: LUMIGAN 0.1 mg/ml contains benzalkonium chloride Do not use the drops when you are wearing your lenses.
Danish: LUMIGAN 0,1 mg/ml indeholder benzalkoniumchlorid Anvend ikke øjendråberne samtidig med, at De bærer kontaktlinser.
English: Citric acid monohydrate
Danish: Dinatriumphosphatheptahydrat Citronsyremonohydrat
English: The following adverse reactions were reported during clinical trials with LUMIGAN 0.3 mg/mL single-dose or in the post-marketing period.
Danish: Følgende bivirkninger blev indberettet i kliniske forsøg med LUMIGAN 0,3 mg/ml enkeltdosisformulering eller i perioden efter markedsføring.
English: General disorders and administration site conditions uncommon asthenia
Danish: Almene symptomer og reaktioner på administrationsstedet ikke almindelig asteni
English: If you use more LUMIGAN 0.1 mg/ml than you should If you use more LUMIGAN than you should, it is unlikely to cause you any serious harm.
Danish: Hvis De har brugt for meget LUMIGAN 0,1 mg/ml Hvis De har brugt for meget LUMIGAN, er det usandsynligt, at det skulle forårsage nogen skade.
English: Ocular use
Danish: Okulær anvendelse
English: • Loss of eye lashes
Danish: • Tab af øjenvipper
English: • Itchiness (up to 14% of people)
Danish: • Kløe (hos op til 14%)
English: There have been a limited number of spontaneous reports of bradycardia or hypotension with bimatoprost 0.3 mg/mL eye drops, solution (multi-dose formulation).
Danish: Der har været et begrænset antal spontane rapporter om bradykardi eller hypotension ved brug af bimatoprost 0,3 mg/ml øjendråber, opløsning (flerdosisformulering).
English: This dose expressed as mg/m2 is at least 210 times higher than the accidental dose of one bottle of LUMIGAN 0.1 mg/ml eye drops, solution in a 10 kg child.
Danish: 210 gange højere end den ved et uheld indtagne dosis af 1 flaske LUMIGAN 0,1 mg/ml øjendråber hos et barn, der vejer 10 kg.
English: Compared to treatment with beta-blocker alone, adjunctive therapy with beta-blocker and LUMIGAN 0.3 mg/ml lowered mean morning (08:00) intraocular pressure by -6.5 to -8.1 mmHg.
Danish: Sammenlignet med monoterapi med beta-blokker sænkede behandling med beta-blokker suppleret med LUMIGAN 0,3 mg/ml middelværdien for intraokulært tryk om morgenen (08.00) med -6,5 til8,1 mmHg.
English: However, once the pouch is opened use within 30 days.
Danish: Dette lægemiddel kræver ikke særlige opbevaringsforhold, men når posen er åbnet, skal den anvendes inden 30 dage.
English: Eye drops, solution 1 x 3 ml
Danish: Øjendråber, opløsning 1 x 3 ml
English: During 12 months' monotherapy treatment with LUMIGAN 0.3 mg/ml in adults, versus timolol, mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mm Hg.
Danish: Under 12 måneders monoterapi med LUMIGAN 0,3 mg/ml hos voksne, hvor der sammenlignedes med timolol, varierede middelændringen i intraokulært tryk (IOT) fra baseline om morgenen (08.00) med -7,9 til -8,8 mmHg.
English: The recommended dose is one drop in the affected eye(s) once daily, administered in the evening.
Danish: Den anbefalede dosis er 1 dråbe i det/de afficerede øje/øjne 1 gang dagligt, inddryppet om aftenen.
English: Eye drops, solution 5 x 0.4 ml
Danish: Øjendråber, opløsning 5 x 0,4 ml
English: The following adverse reactions were reported during clinical trials with LUMIGAN 0.3 mg/ml eye drops, solution or in the post-marketing period.
Danish: Følgende bivirkninger blev indberettet i kliniske forsøg med LUMIGAN 0,3 mg/ml øjendråber eller i perioden efter markedsføring.
English: There have been a limited number of spontaneous reports of bradycardia or hypotension with bimatoprost 0.3 mg/ml eye drops, solution.
Danish: Der har været et begrænset antal spontane rapporter om bradykardi eller hypotension ved brug af bimatoprost 0,3 mg/ml øjendråber.
English: What LUMIGAN 0.3 mg/mL single-dose looks like and contents of the pack LUMIGAN 0.3 mg/mL single-dose is a clear, colourless solution supplied in single-dose plastic containers, each containing 0.4 ml of solution.
Danish: LUMIGAN 0,3 mg/ml enkeltdosis er en farveløs, klar opløsning i enkeltdosisbeholdere af plastik med 0,4 ml opløsning
English: Carton containing 5 single-dose containers,
Danish: Æske med 5 enkeltdosisbeholdere,